Page URL: https://www.bionews.org.uk/page_160135

American organisations join together to develop gene therapies

1 November 2021
Appeared in BioNews 1119

The National Institutes for Health (NIH), Food and Drug Administration (FDA) and 15 pharmaceutical and non-profit organisations have joined together to accelerate the development of gene therapies in the USA.

Taken together, rare diseases affect an estimated 30 million Americans. Forming the Bespoke Gene Therapy Consortium (BGTC), the partnership is hoping to overcome obstacles and streamline the gene therapy development process to provide customised treatments for people affected by rare diseases. 

'The BGTC aims to make it easier, faster and less expensive to pursue bespoke gene therapies in order to incentivise more companies to invest in this space and bring treatments to patients.' said Dr Joni Rutter, acting director of NIH's National Centre for Advancing Translational Sciences.

There are thought to be at least 7000 rare diseases and since most can be traced to variations or changes in a single gene, gene therapy provides a promising therapeutic approach in many cases. However, gene therapy development for rare disease is highly complex, expensive and time-consuming.

'Because any given rare disorder affects so few patients, companies often are reluctant or unable to invest the years of research and millions of dollars necessary to develop, test and bring individualised gene therapy treatments for a single disease to market,' noted Dr Rutter.

So how exactly are the consortium planning on overcoming these issues? By using a common gene delivery vehicle known as the adeno-associated virus (AAV) to deliver or activate therapeutic genes within patients' cells.

The consortium will focus on developing a better understanding of how AVV works. The programme then plans to implement between four and six clinical trials for different rare diseases that have no therapies in development, with the aim to reduce the time between testing animal models of the disease and human clinical trials. Expected outcomes include standardised analytical tests for viral vectors to improve efficiency of manufacturing processes and a streamlined regulatory process for the FDA approval of gene therapies to speed up access to these therapies for people who could benefit.

'There are now significant opportunities to improve the complex development process for gene therapies that would accelerate scientific progress and, most importantly, provide benefit to patients by increasing the number of effective gene therapies.' said Dr Francis Collins, NIH director.

SOURCES & REFERENCES
NIH, FDA and 15 private organizations join forces to increase effective gene therapies for rare diseases
National Institutes of Health |  27 October 2021
NIH, FDA spearhead broad partnership to speed gene therapy research
BioPharma Dive |  28 October 2021
Public-private partnership launched to accelerate gene therapies for rare diseases
StatNews |  27 October 2021
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
20 December 2021 - by Francesca Gavins 
Former head of the Human Genome Project, physician and geneticist, Francis Collins has resigned from his role of the head of the US National Institutes of Health in Bethesda, Maryland...
25 October 2021 - by James Moore 
Gene therapy given to children born with a deadly immune disease remains safe and effective ten years on, researchers report...
25 October 2021 - by Dr Ara Schorscher-Petcu 
A gene silencing treatment for a rare, but debilitating genetic disorder has been recommended for NHS use by the National Institute for Health and Care Excellence....
6 September 2021 - by Dr Rachael Boyle 
A new anti-cholesterol injection has been accepted for use on the NHS, and may soon be available to patients in an effort to prevent heart attacks and strokes...
16 August 2021 - by Dr Charlotte Douglas 
A genome-editing-based gene therapy for blood diseases sickle cell disease and beta-thalassaemia continues to be effective more than two years after treatment...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.